After participating in this educational activity, attendees should be able to:

1) Describe the role of cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis

2) Assess the primary literature regarding efficacy and safety of elexacaftor/tezacaftor/ivacaftor that led to its recent FDA approval  for certain patients with cystic fibrosis

3) Define which patients are appropriate for treatment with elexacaftor/tezacaftor/ivacaftor 

4) Describe how elexacaftor/tezacaftor/ivacaftor impacts the future of cystic fibrosis treatment



Jenna Lee, PharmD 
PGY1 Community-Based Pharmacy Resident
Baystate Medical Center 

None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.


Session date: 
12/16/2019 - 2:00pm to 3:00pm EST
Baystate Medical Center
759 Chestnut Street
Springfield, MA 01199
United States
  • 1.00 ACPE Contact Hours

Please login or register to take this course.